focused on Tumour Responses and Tumour Stress. The first two talks were presented by Eileen White (Rutgers University, New Jersey) and myself and were related to the regulation and role of autophagy in tumour development and tumour therapy. Eileen gave an excellent talk on the contribution of autophagy to tumour suppression while I talked about our work involved in identifying signalling pathways that regulate autophagy in response to hypoxia. As a natural follow-on came a talk from Amato Giaccia (Stanford, Paol Alto) who talked about his seminal work to identify drugs that work in a synthetically lethal manner under hypoxic conditions. Johanna Ivaska (Turku) gave the last talk of this session in relation to her outstanding studies on the role of integrin traffic in cell division and aneuploidy.

The final session of the meeting was focused on cell signalling and was Chaired by Nick Hastie, Edinburgh. Mandy Fisher (Imperial College, London) opened the session with a talk about her work on stem cells and this was followed by two talks on the role of ubiquitin in biological processes presented by Ivan Dikic (Goethe University, Frankfurt) and Stefano Piccolo (University of Padua).

The honour of the last talk of the meeting was given to Mike Hall (University of Basel) who talked about his excellent recent in vivo work focused in understanding the mTOR signalling pathway.

All in all, this years meeting was a resounding success with quality presentations throughout. Year by year, the meeting has grown in standing while retaining an atmosphere that is highly interactive and totally egalitarian. We look forward therefore to the continued success of this meeting and to seeing as many of you as possible in Warwick in 2009 and the years to come.

Kevin Ryan, Beatson Institute for Cancer Research (On behalf of the ‘Genes and Cancer Organising Committee’)

---

**First Announcement**

The Centre for Cancer Research Nottingham (CRN), in conjunction with the British and European Associations for Cancer Research (BACR and EACR), is pleased to announce the 6th annual **Cancer Research Summer School** on New Developments in Translational Cancer Research AND **1-day International Symposium** on **Cancer Drug Discovery, Development and Evaluation**

**Invited speakers at the 1-day symposium include:**

- Anne-Lise Borresen-Dale: Institute for Cancer Research, Norwegian Radium Hospital, Oslo, Norway
- Jörg R. Schlehofer: Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
- Michael Seckl: Imperial College of Science, Technology and Medicine, London, UK
- Beverly A. Teicher: Genzyme Corporation, USA
- Ruth Plummer: Northern Institute for Cancer Research, Newcastle upon Tyne, UK
- Paul J Smith: Cardiff University, Cardiff, UK
- John Hartley: UCL Cancer Institute, University College London, UK

The 2-day Summer School will be held on **1st and 2nd July 2009** at the University of Nottingham and will be followed by the 1-day Symposium on **3rd July 2009**.

Individuals can register for events separately or as a combined package. The Summer School will follow the highly successful format of previous years, mixing teaching (overview) presentations on contemporary topics in the field with practical demonstrations.

Registration fees, that cover attendance, food and refreshments, are: Summer School and Symposium: £150/£50 (Full rate/Student rate) Symposium only: £70/£30 (Full rate/Student Rate).

Full programmes and registration details, will be available shortly and can be viewed either via the BACR or EACR websites (www.bacr.org.uk and www.eacr.org respectively). A limited number of Travel Bursary Awards are available to non-UK based participants. Poster Prizes: 1 Winner and 2 “Highly Commended” Awards will be made on Friday 3rd July 2009. Further information is also available from Jane Doughty – janeh.doughty@nottingham.ac.uk and Kathryn Wass – kathryn.wass@nottingham.ac.uk – University of Nottingham, UK.
Clinical & Translational Oncology is the official publication of the Spanish Federation of Cancer Societies (FESEO) and its affiliated societies, including ASEICA. After an almost one full year of evaluation, Thomson Reuters has recently communicated to FESEO their decision to select this journal for coverage into two of its world-wide recognized indexes, Science Citation Index Expanded (also known as SciSearch”) and Journal Citation Report/Science Edition. The journal will be indexed and abstracted since volume 9, issue 1 (January 2007).

It is great news that the journal successfully passed the evaluation, specially the first time it was considered. Also, it is important to point out that Clinical & Translational Oncology is the first journal dedicated to oncology fully managed and printed in Spain, that is included in these important indexes. In this regard, it is an historical achievement. This successful outcome has been feasible thanks to the strategic alliance with the publisher Springer.

Clinical & Translational Oncology will maintain its efforts to bring to basic and clinical oncologists in a clear, easy to read and educational format, the most recent advances that will help understanding the molecular and cellular biology of tumours and the efforts to identify new drug targets as well as the development of new therapeutical strategies against specific tumours actually in progress both at the laboratory and the clinical level. Finally, the technological improvements that provide the necessary tools to progress both in research and treatment of cancer will be also covered in an effort to facilitate the continuous update of researchers and clinicians. This effort will allow to gain for Clinical & Translational Oncology a clear recognition and leadership in the transition from Clinical Oncology to Translational Oncology at the international level. In addition, a special effort will be dedicated to complement these Educational Series in Translational Oncology with multidisciplinary clinical revisions dedicated to most kinds of tumours. This new Series will help clinical oncologist to be updated on those recent advances, clinical consensus, special focussed conferences, and new trends in the management of cancer patients.

ASEICA has played a critical role in the progress Clinical & Translational Oncology has made and will continue supporting its future development. The EACR is an affiliated society of Clinical & Translational Oncology.

Dr. Juan Carlos Lacal
Professor of Research
Translational Oncology Unit
CSIC-UAM- La Paz Centro Nacional de Biotecnología
C/ Darwin 3, Campus de Cantoblanco 28049 Madrid, Spain

We are pleased to announce that Professor Andy Gescher (University of Leicester) has succeeded Professor Robert Brown (Imperial College) as the new Chairman of the BACR.

The BACR continues to develop its programme of focused conferences and to support its members, to enable attendance at scientific meetings or training/exchange visits to laboratories.

During the past year BACR organised, three focused meetings:

“Cellular Immortality and Cancer: From Telomerase to Cancer Stem Cells” in June at Stratford on Avon

“Advances in Cancer Drug Discovery” in September at Cambridge

“Preclinical Models: Biomarkers and Targeted Therapy” in November at London. The meeting was organised jointly with the Royal Society of Medicine Oncology Section and the Academy of Pharmaceutical Sciences.

Topics of planned BACR Special Conferences for 2009 are:

“Cancer Immunotherapy: Regulatory Paradigms, Biomarkers/Clinical Endpoints, Technological Approaches”, jointly organised with the British Society of Immunology, 19th May, London

“Translational Regulation and Micro RNAs in Cancer”, jointly organised with the Royal Society of Medicine Oncology Section, 18 November, London

“In 2010 the BACR celebrates its 50th anniversary and to mark the occasion there will be a meeting in Edinburgh (13th-15th June) and the focus of the meeting will be on revisiting “the hallmarks of cancer” 10 years after the seminal paper on that topic by Weinberg and Hanahan.